Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 9/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | GHSR | Q92847 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1012064 | 1.00 | FAAH (0.39) | FAAHBTKGAAMEN1KMT2A | |
| SCHEMBL8981350 | 1.00 | FAAH (0.39) | FAAHBTKGAAMEN1KMT2A | |
| SCHEMBL8980908 | 1.00 | FAAH (0.39) | FAAHBTKGAAMEN1KMT2A | |
| SCHEMBL550992 | 1.00 | FAAH (0.39) | FAAHBTKGAAMEN1KMT2A | |
| SCHEMBL76966 | 0.98 | BTK (0.38) | FAAHBTKGAAMEN1KMT2A | |
| SCHEMBL202837 | 0.95 | BTK (0.38) | FAAHBTKGAAMEN1KMT2A | |
| SCHEMBL142219 | 0.91 | MEN1 (0.39) | BTKGAAMEN1KMT2AMAPK1 | |
| SCHEMBL27646197 | 0.87 | GAA (0.37) | FAAHBTKGAAMEN1KMT2A | |
| SCHEMBL15116645 | 0.86 | GAA (0.36) | FAAHBTKGAAMEN1KMT2A | |
| SCHEMBL2789711 | 0.85 | GHSR (0.37) | FAAHBTKGAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 336 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109824545-B | Preparation method of trans-4-N-Boc-aminocyclohexane carboxylic acid | 泰州精英化成医药科技有限公司 | 2021-02-26 | — | — | CN | claimed |
| CN-105085296-B | The method that one kind prepares trans 4 (t-butoxycarbonyl amino) cyclohexanecarboxylic acid intermediate isomerization | 常州齐晖药业有限公司 | 2017-08-08 | — | — | CN | claimed |
| WO-2013033520-A1 | A METHOD FOR REGULATING SKIN PIGMENTATION | THE GENERAL HOSPITAL CORPORATION (US) | 2013-03-07 | — | — | WO | claimed |
| US-7276496-B2 | Cyclic malonamides as inhibitors of Aβ protein protection | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-10-02 | — | — | US | claimed |
| US-12583825-B2 | Benzo[h]quinazolin-4-amine and thieno[3,2-h]quinazolin-4-amine derivatives for the treatment of cancer | Redona Therapeutics, Inc. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12527779-B2 | Prostaglandin E2 (PGE2) EP4 receptor antagonists | DOMAIN THERAPEUTICS (FR) | 2026-01-20 | — | — | US | disclosed |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PEPTIDREAM INC (JP) | 2026-01-15 | — | — | US | disclosed |
| EP-4568959-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2025-06-18 | — | — | EP | disclosed |
| CN-119930740-A | Dipeptide compound, chimeric molecule based on dipeptide compound and application of dipeptide compound | 西南交通大学 | 2025-05-06 | — | — | CN | disclosed |
| WO-2025090774-A1 | CHEMOTHERAPEUTIC COMPOUNDS AND METHODS OF USE | SEAGEN INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| US-20250114313-A1 | OLIGO-BENZAMIDE ANALOGS AND THEIR USE IN CANCER TREATMENT | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-04-10 | — | — | US | disclosed |
| EP-4534524-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PeptiDream Inc. (JP) | 2025-04-09 | — | — | EP | disclosed |
| US-5175146-A | Improved potency; storage stability; nonhydrolyzing; osteoporosis; Paget's disease; hypocalcemic | VICAL, INC. (US) | 1992-12-29 | — | — | US | disclosed |
| EP-0513974-A1 | Novel benzo-fused lactams that promote the release of growth hormone | MERCK & CO. INC. (US) | 1992-11-19 | — | — | EP | disclosed |
| CN-1066070-A | Promote the new benzo-fused lactams that tethelin discharges | MERCK & CO INC (US) | 1992-11-11 | — | — | CN | disclosed |
| WO-1992016524-A1 | BENZO-FUSED LACTAMS PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | disclosed |
| EP-0480969-A1 | AMINO ACID ANALOG CCK ANTAGONISTS | ABBOTT LABORATORIES (US) | 1992-04-22 | — | — | EP | disclosed |
| WO-1991000725-A2 | AMINO ACID ANALOG CCK ANTAGONISTS | ABBOTT LABORATORIES (US) | 1991-01-24 | — | — | WO | disclosed |
| EP-0310918-A2 | Peptide-like amino-acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-04-12 | — | — | EP | disclosed |
| US-4297489-A | CEPHALOSPORINS | BRISTOL-MYERS COMPANY (US) | 1981-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527779-B2 | Prostaglandin E2 (PGE2) EP4 receptor antagonists | PTGER1, PTGER4, PTGER3 | FAAH 279/4885BTK 3996/4885GAA 4880/4885 |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | NSUN3, BCAT1, SLC43A1 | FAAH 3992/4885BTK 2244/4885GAA 2026/4885 |
| US-20250114313-A1 | OLIGO-BENZAMIDE ANALOGS AND THEIR USE IN CANCER TREATMENT | GAA, LIPA, LIPE | FAAH 620/4885BTK 1337/4885GAA 1/4885 |
| US-12583825-B2 | Benzo[h]quinazolin-4-amine and thieno[3,2-h]quinazolin-4-amine derivatives for the treatment of cancer | H1-3, RB1, H1-2 | FAAH 1895/4885BTK 54/4885GAA 4135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.